




orenitram[®]
treprostiniil
EXTENDED-RELEASE TABLETS

90-DAY
TRIAL
PROGRAM

.....

Orenitram[®] (treprostiniil)

The Orenitram 90-Day Trial Program lets you try Orenitram at no cost

.....

After the trial period, your healthcare provider will determine if you should continue taking Orenitram.

Please see complete Important Safety Information on page 7 and the Full Prescribing Information and Patient Information for Orenitram in pocket.


orenitram[®]
treprostiniil
EXTENDED-RELEASE TABLETS

Getting started with Orenitram

Welcome to the Orenitram 90-Day Trial Program. Your healthcare provider has enrolled you in this program to receive Orenitram for up to 90 days at no cost to help treat your pulmonary arterial hypertension (PAH).* To get you started on this program, let us first introduce you to Orenitram.

Why Orenitram?

People with PAH may not produce enough prostacyclin, which is a natural chemical in your body that helps keep the blood vessels in your lungs open. Orenitram is a man-made form of prostacyclin, called a "prostacyclin mimetic." This means that it treats PAH by mimicking some of the effects of the natural prostacyclin your body lacks.^{1,2}

- Orenitram helps keep the blood vessels in your lungs open, which may make it easier for your heart to pump blood through your lungs¹
- By taking Orenitram, you could slow down PAH and see improvements in your daily symptoms and ability to function¹



Want to know more? Visit [Orenitram.com](https://www.orenitram.com) to learn more about how Orenitram may help.

WHAT IS ORENITRAM?

Orenitram is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of your lungs. Orenitram can help slow down the progression of your disease and improve your ability to exercise. It is not known if Orenitram is safe and effective in children.

IMPORTANT SAFETY INFORMATION for Orenitram

Who should not take Orenitram?

Do not take Orenitram if you have severe liver problems.

Please see complete Important Safety Information on page 7 and the Full Prescribing Information and Patient Information for Orenitram in pocket.

*After the trial period, your healthcare provider will determine if you should continue taking Orenitram.



90-DAY TRIAL PROGRAM

The Orenitram 90-Day Trial Program



Once you are enrolled in the Orenitram 90-Day Trial Program, the United Therapeutics Access Solutions and Support Team (ASSIST®) and Lash Group Specialty Pharmacy will contact you to verify your information, provide more details about the program, and review the next steps. It's important to answer these calls to get your trial program started.

During your 90-day trial, you will receive:



Scheduled home visits and training led by Lash nurses



Coordinated shipment of your medication



Additional support from nurses and pharmacists at the direction of your doctor



Once you have been enrolled, if you have questions, please contact ASSIST at 1-877-UNITHER (1-877-864-8437).



Taking Orenitram

Your Orenitram dose

Your doctor will tell you how often to take Orenitram (every 8 hours or every 12 hours) and how to adjust your dose as you continue to take it. With 5 different dose strengths available, your doctor has flexibility in finding the dose combination that is right for you.¹



Tablets not shown at actual size.

Throughout the 90-Day Trial Program, you should take Orenitram exactly as your doctor tells you to take it. Changes in your dose over time will be based on what works best for your PAH symptoms and how you tolerate taking Orenitram.¹ As your Orenitram dose changes, the Lash Group Specialty Pharmacy will also reach out to you.

Be open with your healthcare team about any side effects that bother you, get worse over time, or do not go away so they can find ways to help.

Please see the back cover to help you proactively discuss a plan for side effect management with your healthcare provider.



If you have any questions about your Orenitram dose or dosing schedule, contact your healthcare provider.

IMPORTANT SAFETY INFORMATION for Orenitram

What should I tell my healthcare provider before taking Orenitram?

Tell your healthcare provider:

- If you have liver problems or diverticulosis.
- If you are pregnant, breastfeeding, and/or plan to become pregnant or breastfeed. It is not known if Orenitram will harm your unborn baby or if Orenitram passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with Orenitram.
- **About all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Orenitram and other medicines may affect each other causing side effects. Do not start any new medicine until you check with your healthcare provider. Especially tell your healthcare provider if you take another medicine that contains treprostinil, such as Remodulin® or Tyvaso®.

Please see complete Important Safety Information on page 7 and the Full Prescribing Information and Patient Information for Orenitram in pocket.



What happens after the 90-Day Trial Program?

Around day 60, ASSIST will reach out to your healthcare provider for direction about whether you will continue treatment beyond the Orenitram 90-Day Trial Program. Your healthcare provider will determine if you should continue taking Orenitram after the trial.

If you and your healthcare provider decide you should stop taking Orenitram, you will need to titrate off of therapy (slowly decrease your dosage). **Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider.** Stopping Orenitram suddenly may cause worsening of your PAH symptoms.¹

If you and your healthcare provider decide you should continue taking Orenitram, you will receive more information from ASSIST.

For more information about Orenitram, please see the Full Prescribing Information and Patient Information in pocket.


orenitram[®]
treprostinil
EXTENDED-RELEASE TABLETS

Orenitram 90-Day Trial Program Terms & Conditions

The Orenitram 90-Day Trial Program (“Trial Program”) is offered by United Therapeutics Corporation. To utilize this Trial Program, you must have a valid prescription for an FDA-approved use of Orenitram. There is no obligation to continue Orenitram after the 90-Day Trial Program. If the decision is made to continue therapy, a separate prescription must be written by your healthcare provider and dispensed by one of United Therapeutics Corporation’s contracted specialty pharmacies, Accredo or CVS Specialty. Patients may be offered the Trial Program exclusively through their healthcare provider.

Terms and Conditions for Trial Program

By enrolling in the 90-Day Trial Program for Orenitram, you acknowledge that you currently meet the eligibility criteria and will comply with the Terms and Conditions described below:

1. Only new patients with a valid prescription for an FDA-approved use of Orenitram may use this Trial Program. This **Trial Program** is not valid for patients transitioning to Orenitram from Tyvaso or Remodulin. By enrolling in this Trial Program, you certify that: (a) you are not currently using and have not previously used Orenitram outside of the hospital setting (i.e. “Outpatient”), and (b) you are not currently taking an inhaled or infused prostacyclin.
2. Patients are not eligible to start the Trial program in the hospital setting (i.e. “Inpatient”).
3. Product cannot be shipped to a hospital, physician’s office, etc. Product must be shipped directly to the patient.
4. This offer is only valid for those patients 18 years and older.
5. Only 1 enrollment per patient may be redeemed under this program; no photocopies or reproductions of the enrollment form will be accepted.
6. Enrollment is valid for 90 days of Orenitram at no cost to the patient.
7. **No claim for reimbursement for product dispensed pursuant to this Trial Program may be submitted, in whole or part, to any third-party payer, including a public or private payer.**
8. The prescription for the Trial Program cannot be submitted to count towards out of pocket costs under any prescription medicine plan.
9. For Medicare patients, Trial Program product may not count towards “True Out-of-Pocket (TrOOP)” expenses.
10. The Trial Program enrollment form will be accepted only at United Therapeutics Corporation’s contracted pharmacy for this Program, Lash and Group. Offer not valid if submitted to any other pharmacy.
11. This enrollment form is not transferable. It is illegal for any person to sell, purchase, or trade, or offer to sell, purchase, or trade or to counterfeit this voucher.
12. This 90-Day Trial Program cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription.
13. **This free trial is not health insurance.**
14. United Therapeutics Corporation makes no express or implied guarantee that Orenitram will be covered by any third-party payer after the 90-day trial period.
15. Offer good only in the United States and Puerto Rico.
16. United Therapeutics Corporation reserves the right to rescind, revoke, or amend this free trial program at any time without notice.

Please see complete Important Safety Information on page 7 and the Full Prescribing Information and Patient Information for Orenitram in pocket.

WHAT IS ORENITRAM?

Orenitram is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of your lungs. Orenitram can help slow down the progression of your disease and improve your ability to exercise. It is not known if Orenitram is safe and effective in children.

IMPORTANT SAFETY INFORMATION for Orenitram

Who should not take Orenitram?

Do not take Orenitram if you have severe liver problems.

What should I tell my healthcare provider before taking Orenitram?

Tell your healthcare provider:

- If you have liver problems or diverticulosis.
- If you are pregnant, breastfeeding, and/or plan to become pregnant or breastfeed. It is not known if Orenitram will harm your unborn baby or if Orenitram passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with Orenitram.
- **About all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Orenitram and other medicines may affect each other causing side effects. Do not start any new medicine until you check with your healthcare provider. Especially tell your healthcare provider if you take another medicine that contains treprostinil, such as Remodulin® or Tyvaso®.

How should I take Orenitram?

- **Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider.**
- Orenitram is usually taken 3 times a day (about every 8 hours) or 2 times a day (about every 12 hours). Your healthcare provider will tell you how often you should take Orenitram. If you have side effects, your healthcare provider may tell you to change your dose or when you take Orenitram. Take Orenitram with food.
- Swallow Orenitram tablets whole. Do not split, chew, crush, or break your Orenitram tablets. Do not take Orenitram tablets that are damaged or broken. **If Orenitram tablets are not taken whole, they may release too much medicine at one time. This can lead to side effects.**
- If you miss your dose of Orenitram, take the missed dose as soon as possible with food.
- If you miss 2 or more doses of Orenitram, call your healthcare provider to see if you need to change your dose.
- If you take too much Orenitram, call your healthcare provider or go to the nearest hospital emergency room right away.
- You may see the tablet shell in your stools (bowel movements). This is usually normal. The tablet shell is not digested. If you have diverticulosis, the tablet shell may get stuck in a blind pouch or diverticulum in your intestine.

What are the possible side effects of Orenitram?

Orenitram can cause serious side effects, including worsening of PAH symptoms.

- Stopping Orenitram suddenly may cause worsening of your PAH symptoms. **Do not change your dose or suddenly stop taking Orenitram without first talking to your healthcare provider.**
- **The most common side effects of Orenitram include** headache, diarrhea, nausea, vomiting, flushing, and pain in arms, legs, and jaw. These are not all of the possible side effects of Orenitram. Tell your healthcare provider if you have any side effect that bothers you or does not go away.
- Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.

The risk information provided here is not comprehensive. To learn more about Orenitram, talk with your healthcare provider. Please see Full Prescribing Information and Patient Information at www.orenitram.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).

OREISIconOCT19


orenitram[®]
treprostinil
EXTENDED-RELEASE TABLETS

Side effect management

Planning ahead with your healthcare provider

Prostacyclin-class therapies, such as Orenitram, can have wide-ranging effects throughout the body, and it may take time for your body to adjust. The most common side effects experienced by patients include headache, diarrhea, nausea, vomiting, flushing, and pain in arms, legs, and jaw.¹

- Talk with your doctor about potential side effects so you know what to expect
- Have a plan for managing side effects in place ahead of time to help increase your chance of treatment success

Use the space below to write down your plan, including additional medications, supplements, or other techniques to help lessen side effects.

Prescription*	OTC	Medication	Intended use
<input type="checkbox"/>	<input type="checkbox"/>	_____	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____	_____

Additional notes

*These medications will require a prescription from your doctor.
OTC=over the counter.



If you have questions or are experiencing any side effects, contact your healthcare team. Together, you can work toward a solution.

Who to call: _____

Please see complete Important Safety Information on page 7 and the Full Prescribing Information and Patient Information for Orenitram in pocket.



References: 1. Orenitram [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2019. 2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. *N Engl J Med.* 2004;351(14):1425-1436.



Orenitram and ASSIST are registered trademarks of United Therapeutics Corporation.
© 2020 United Therapeutics Corporation. All rights reserved. US/ORE/0402 Printed in USA.

EXTENDED-RELEASE TABLETS